Antikoagulationsparametrene bør monitoreres især i de første dage efter behandlingsstart eller dosisændring af celecoxib hos patienter, som tager warfarin eller andre antikoagulantia, da disse patienter har en øget risiko for blødningskomplikationer.
4.5 Interaction with other medicinal products and other forms of interaction Pharmacodynamic interactions Anticoagulant activity should be monitored particularly in the first few days after initiating or changing the dose of celecoxib in patients receiving warfarin or other anticoagulants since these patients have an increased risk of bleeding complications.